Merck & Co.
AWARDS
NEWS
The COVID-19 pandemic is having a devastating effect on global business and biopharma companies are not excluded.
Ken Pienta, acting chief medical officer of Cue Biopharma, said the researchers believe that CUE-101 may lead to enhanced anti-tumor activity in combination with Merck’s powerhouse checkpoint inhibitor.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 21, 2020.
BioSpace takes an in-depth look at the human immunodeficiency virus including research, drugs in the pipeline and treatments. Check out the free downloadable report.
Rexahn said it notified Merck on April 7 of its decision to discontinue the development of RX-5902 for the treatment of metastatic triple-negative breast cancer.
While the world is working to slow the COVID-19 pandemic by social isolation and quarantine, numerous companies globally are working to develop a vaccine against the virus.
JOBS
IN THE PRESS